Given that GDM is linked to more severe adipose inflammation, our findings raise the possibility that FGF21 signaling and its downstream metabolites may serve as alternative therapeutic strategies for GDM, particularly in cases of FGF21 resistance. The gene discussed is FGF21; the disease is gestational diabetes.